Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
Ciccullo A, Baldin G, Capetti A, Borghi V, Sterrantino G, Latini A, Madeddu G, Celani L, Vignale F, Rossetti B, Dusina A, Cossu MV, Restelli S, Gennari W, Lagi F, Giacomelli A, Colafigli M, Brescini L, Borghetti A, Mussini C, Rusconi S, Di Giambenedetto S. Ciccullo A, et al. Among authors: cossu mv. BMJ Open. 2019 Dec 2;9(12):e029960. doi: 10.1136/bmjopen-2019-029960. BMJ Open. 2019. PMID: 31796476 Free PMC article.
Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study.
Cattaneo D, Cossu MV, Fucile S, Riva A, Baldelli S, Meraviglia P, Landonio S, Impagnatiello C, Resnati C, Galli M, Clementi E, Capetti A, Rizzardini G, Gervasoni C. Cattaneo D, et al. Among authors: cossu mv. Ther Drug Monit. 2015 Feb;37(1):119-25. doi: 10.1097/FTD.0000000000000114. Ther Drug Monit. 2015. PMID: 24988438 Clinical Trial.
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, Rusconi S, Riccardi N, Baldin GM, Cima S, Niero FP, Rizzardini G, Sasset L. Capetti AF, et al. Among authors: cossu mv. Antivir Ther. 2017;22(3):257-262. doi: 10.3851/IMP3095. Epub 2016 Sep 23. Antivir Ther. 2017. PMID: 27661787
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.
Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group. Borghetti A, et al. Among authors: cossu mv. AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. AIDS. 2017. PMID: 28079545 No abstract available.
Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, Rusconi S, Riccardi N, Baldin GM, Cima S, Niero FP, Rizzardini G, Sasset L. Capetti AF, et al. Among authors: cossu mv. Antivir Ther. 2017;22(3):273-275. doi: 10.3851/IMP3109. Epub 2016 Nov 28. Antivir Ther. 2017. PMID: 28400541 No abstract available.
75 results